

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 March 2024 (21.03.2024)



(10) International Publication Number
WO 2024/056561 A1

(51) International Patent Classification:

B01D 15/16 (2006.01) **C12N 15/861** (2006.01)
B01D 15/36 (2006.01) **C12N 15/86** (2006.01)
B01D 15/42 (2006.01)

(21) International Application Number:

PCT/EP2023/074823

(22) International Filing Date:

11 September 2023 (11.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22195241.9 12 September 2022 (12.09.2022) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **D'ATRI, Valentina**; c/o University of Geneva, 24, rue du Général-Dufour, 1211 Geneve 4 (CH). **GUIL-LARME, Davy**; c/o University of Geneva, 24, rue du Général-Dufour, 1211 Geneve 4 (CH). **ELGER, Carsten**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **KOCHARDT, Dominik**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **RUPPERT, Raphael**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE).

(74) Agent: **MIZBANI, Dr. Amir**; c/o F. Hoffmann-La Roche AG, Patent Department, Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: METHOD FOR SEPARATING FULL AND EMPTY AAV PARTICLES

(57) Abstract: Herein is reported a method for separating full and empty recombinant adeno-associated virus particles using an anion exchange chromatography step, wherein the method comprises a sequence of applying a solution comprising empty and/or full rAAV particles to an anion exchange chromatography material inside a chromatography column, a first isocratic step, a first linear gradient, a second isocratic step and a second linear gradient, wherein the empty recombinant adeno-associated virus particles are eluted during the first linear gradient and the full recombinant adeno-associated virus particles are eluted during the second linear gradient. In certain embodiments, the solution applied in the first isocratic step comprises about (65) mM of the buffer substance, about (10) mM of the elution salt, about (2) mM of the salt and has a pH value of about 9.4. In certain embodiments, the solution applied in the second isocratic step comprises about (65) mM of the buffer substance, about (90) mM of the elution salt, about (2) mM of the salt and has a pH value of about 9.4. In certain embodiments, the buffer substance is N-(1,1-Dimethyl- (2)-hydroxyethyl)-(3)-amino-2-hydroxypropane sulfonic acid, the elution salt is tetramethyl ammonium chloride, and the salt is magnesium chloride.

WO 2024/056561 A1